Lack of impact of radiologic septal measurements upon patient symptoms and performance of septoplasty during endoscopic sinus surgery*

Nicholas R. Rowan^{1,2}, Zachary M. Soler¹, Jess C. Mace³, Marc P. Camilon¹, Charles Palmer¹, Rabun H. Jones¹, Timothy L. Smith³, Rodney J. Schlosser^{1,4}

¹ Division of Rhinology and Sinus Surgery, Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina. Charleston, SC, USA

² The Johns Hopkins University School of Medicine, Department of Otolaryngology-Head and Neck Surgery, Baltimore, MD, USA ³ Oregon Health & Science University, Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology and Sinus/ Skull Base Surgery, Portland, OR, USA

⁴Department of Surgery, Ralph H. Johnson VA Medical Center, Charleston, SC, USA

Rhinology 58: 4, 323 - 332, 2020 https://doi.org/10.4193/Rhin19.412

*Received for publication: November 12, 2019 Accepted: January 20, 2020

Abstract

Background: Recent literature suggests that concurrent septoplasty during endoscopic sinus surgery (ESS) improves patient outcomes, however, the underlying indications for performing concurrent septoplasty are unknown. The objective of this study was to investigate the relationship between objective radiologic measures of nasal septal deviation with preoperative patient symptomatology and measures of CRS disease severity. We also sought to understand the association of objective radiologic measurements with surgeon performance of concurrent septoplasty during ESS.

Methodology: Seventy-four patients with CRS undergoing ESS were prospectively enrolled. Angles of septal deviation, intranasal areas and volumes were assessed on preoperative computed tomography (CT) scans and correlated with a robust battery of patient reported outcomes measures (PROMs), objective measures of CRS severity including olfaction scores, radiologic and endoscopic staging, and performance of septoplasty.

Results: Intranasal areas and volumes demonstrated only weak linear associations with patient-reported nasal congestion, however, angles of septal deviation alone did not correlate with congestion or any other PROM measure. Meanwhile, radiologic septal-related measurements did not correlate with objective measures of CRS disease severity or the performance of a concurrent septoplasty.

Conclusions: Though prior studies demonstrate improved patient outcomes in the setting of concurrent septoplasty during ESS, this study failed to establish an association between preoperative radiologic septal-related measurements and patient symptomatology or surgeon decision to perform septoplasty. Although objective factors to identify patients most likely to benefit from concurrent septoplasty remain unidentified, the potential improvement of surgical recommendations and patient outcomes makes this an important area of continued investigation.

Key words: chronic rhinosinusitis, septoplasty, sinus surgery, quality of life, olfaction disorders

Introduction

Numerous studies have examined the effectiveness of rhinologic surgeries on patient outcomes, two of the most common being nasal septoplasty and endoscopic sinus surgery (ESS). Independently, both procedures have been shown to lead to improvements in disease-specific quality-of-life (QOL) metrics^(1,2), however, the impacts of performing both surgeries concurrently on outcomes and the surgical indications for doing so are less clear.

In 2011, Rudmik et al. directly investigated this question by



Figure 1. Example of measurement for nasal bone angle (A), inferior turbinate angle (B), crista galli angle (C), and the globe / optic nerve angle (D).

comparing a cohort of patients with chronic rhinosinusitis without nasal polyposis (CRSsNP) who underwent ESS alone to those who underwent ESS with a concurrent septoplasty, and concluded that septoplasty is not a confounding factor in QOL measures⁽³⁾. However, more recent investigations have reported that concurrent septoplasty is associated with improved patient-reported and surgical outcomes^(4, 5). In one study, 22item Sinonasal Outcome Test (SNOT-22) survey scores averaged greater than 1 minimal clinically important difference (MCID) in patients who underwent a concurrent septoplasty. Interestingly, there was significant variation between practices for performing septoplasty, and patient improvements were largely driven by the ear/facial and psychological domains of the SNOT-22 instrument⁽⁵⁾. Meanwhile, another study demonstrated a lower relative risk of revision sinus surgery when a concurrent septoplasty was performed (OR=0.70)⁽⁴⁾. To this end, the most recent evidence suggests that concurrent septoplasty may improve patient outcomes, however the mechanism by which that is accomplished is unknown.

In light of these findings, our primary objective was to determine if specific objective criteria, such as radiologic measures of nasal septal deviation, are associated with chronic rhinosinusitis (CRS)-related symptomatology and CRS disease severity. Our secondary objective was to determine if any of these objective measures of septal deviation are associated with surgeon performance of concurrent septoplasty during ESS in patients with CRS. Identification of specific radiologic metrics associated with patient symptomatology and surgical outcomes could potentially guide and standardize surgeon performance of septoplasty during ESS.

Material and methods

Study population

Study participants were recruited within two academic, tertiary



Figure 2. Example of determining the nasal bone area – cm²- (A), inferior turbinate area (B), cristi galli area (C), and the posterior globe / optic nerve area (D).

referral clinics at the Oregon Health and Science University (OHSU; Portland, OR) and the Medical University of South Carolina (MUSC; Charleston, SC). CRS was confirmed using diagnostic criteria described in the Adult Sinusitis Guidelines established by the American Academy of Otolaryngology⁽⁶⁾. Study participants were enrolled in a prospective, observational cohort designed to evaluate patient-reported treatment outcomes surrounding ESS which has been previously described in the literature ^(5, 7-12). Institutional Review Boards (IRB) at both OHSU (IRB#7198) and MUSC (IRB#12409) approved the study. All study participants experienced continued symptoms of CRS after previously completing appropriate medical therapy and were considered surgical candidates per the standard of care, completed surgical counseling, and voluntarily elected ESS. The decision to perform septoplasty and extent of ESS was left to the discretion of the treating surgeon. Though extent of surgery was decided prior to surgery, if surgical access was limited

intraoperatively secondary to a septal deviation, a septoplasty may have been performed to improve access and visualization. Patients requiring management of the nasal valve or caudal septum were excluded from this study, and therefore should be considered non-contributory to this analysis.

Radiologic measurements

Septal deviations can occur in all 3 dimensions and vary from side to side, and as such, angles of septal deviation, nasal cross sectional areas, and nasal volumes were assessed using OsiriX Lite imaging software (Pixmeo; Bernex, Switzerland). Angles of deviation and cross-sectional areas (cm²) were measured in the coronal plane. To ensure the standardization of these measurements, 2 reference coordinates (X,Y) of the most anterior maxillary crest and crista galli were marked, and a vertical reference line between these 2 points was used for each measurement. Next, 4 predetermined locations were identified, including the

most anterior aspect of the nasal bone, the head of the inferior turbinate, the crista galli, and the coronal cut just anterior to the optic nerve (Figure 1). At each anatomical site, a second tangential line was created to the most deviated portion of the nasal septum as shown in Figure 1 and completed bilaterally. Cross-sectional intranasal areas were outlined and calculated at each of the 4 predetermined locations (Figure 2). Total intranasal volumes (cm³) were calculated between the most anterior point of interest (nasal bones) to the most posterior point of interest (optic nerve) using a preprogramed software algorithm. All images used to calculate volumes were reviewed so as to ensure no aberrancies that may have been introduced secondary to mucosal oedema or nasal polyps. Though rigorously performed, these measurements are not a validated measure of nasal geometry.

For data analysis of these metrics, further classification of these measurements was compiled into two independent categories. First, septal deviation on the "worst side" was defined as the side of the nasal airway with the greatest angle of deviation. Second, in an effort to depict the overall, bilateral, impact of deviation from midline, septal measurements were "combined" by summating corresponding values. The "combined" method would also account for differences in intranasal areas and volumes secondary to the nasal cycle. Though potential differences in intranasal areas and volumes secondary to the nasal cycle could have been overcome by applying topical nasal decongests prior to performing a CT scan, non-decongested nasal cavities may be more likely to provide an accurate reflection of active patient symptomatology.

Sinonasal disease severity

Endoscopic examinations were quantified by each enrolling physician using the Lund-Kennedy staging system⁽¹³⁾ and patients' bilateral olfactory function was evaluated using the Brief Smell Identification Test (BSIT; Sensonics International, Haddon Heights, NJ)⁽¹⁴⁾. Preoperative computed tomography (CT) of the sinuses was obtained without contrast, on all patients, prior to ESS and quantified using the Lund-Mackay staging system⁽¹⁵⁾.

Patient-Reported Outcome Measures

Participants were asked to complete a battery of patientreported outcome measures (PROMs) to evaluate preoperative symptom severity across a range of health domains. The SNOT-22 and Rhinosinusitis Disability Index (RSDI) were used to describe sinonasal symptom severity and QOL⁽¹⁶⁻¹⁸⁾. Meanwhile, the SF-6D instrument was used to detail current health states using a normalized health utility value⁽¹⁹⁾, the Patient Health Questionnaire-2 (PHQ-2) was used as a measure of depressive symptoms⁽²⁰⁾, and the Pittsburgh Sleep Quality Index (PSQI) assessed participant sleep quality⁽²¹⁾. Table 1. Preoperative demographics, patient characteristics, and comorbidities of the final study cohort (n=74).

	Mean [SD]	N (%)
Age at enrollment (years)	56.9 [13.8]	
Female*		40 (54%)
Male*		34 (46%)
Medical history / comorbid diagnoses:		
Revision sinus surgery		37 (50%)
Nasal polyposis		29 (39%)
Asthma		24 (32%)
ASA sensitivity		7 (10%)
Allergy (positive mRAST/skin prick)		29 (39%)
Depression*		9 (12%)
Tobacco use/smoking		1 (1%)
Alcohol use		34 (47%)
Oral corticosteroid dependency		9 (12%)
Diabetes mellitus (Type I / II)		7 (5%)
Patient Reported Outcome Measures:		
SNOT-22 total score	54.6 [19.0]	
RSDI total score	48.0 [25.3]	
SF-6D Health utility score	0.68 [0.16]	
PHQ-2 total score	1.7 [1.7]	
Positive depression screen (score > 3)		22 (30%)
PSQI total score	9.1 [4.7]	
Poor sleep quality (score > 5)		47 (67%)
Measures of Disease Severity:		
Lund-Kennedy endoscopy score	6.9 [3.6]	
BSIT total score	8.2 [3.4]	
Abnormal olfaction (score < 8)		30 (42%)
Lund-Mackay CT score	13.5 [6.3]	

*self-reported; SD, standard deviation; ESS, endoscopic sinus surgery; ASA, acetylsalicylic acid; SNOT-22, 22-item SinoNasal Outcome Test survey; BSIT, Brief Smell Identification Test; mRAST, modified radioallergosorbent testing, CT, computed tomography; RSDI, Rhinosinusitis Disability Index; PHQ-2, 2-item Patient Health Questionnaire; PSQI, Pittsburgh Sleep Quality Index.

Statistical analyses

Statistical analysis of data was completed using SPSS (version 24.0) statistical software (IBM Corp., Armonk, NY). Distributions of all scaled measures were assessed for normal distributions to direct appropriate statistical testing. Data normality and outlier identification was assessed using graphical analysis and the Shapiro-Wilk test for both preoperative septal deviation measurements and PROM scores. Descriptive statistics were completed for all study data. All two-tailed, bivariate correlations were completed using either Pearson's correlation coefficients or Spearman's rank coefficients (R), when appropriate.

Table 2. Summary of average septal deviation measurements for both the "worst side" and "combined bilateral" deviation for the total cohort (n=74).

Angle (°):	Worst side deviation	Combined bilateral deviation
	Mean [SD]	Mean [SD]
Nasal bone angle	7.8 [2.8]	13.2 [3.8]
Inferior turbinate angle	10.9 [2.7]	18.4 [4.4]
Crista galli angle	8.2 [3.6]	13.4 [4.7]
Posterior globe/optic nerve angle	7.1 [3.8]	11.5 [4.6]
Intranasal Areas (cm²):		
Nasal bone area	1.6 [1.4]	3.2 [2.0]
Inferior turbinate area	1.4 [1.1]	3.0 [1.9]
Crista galli area	1.7 [1.4]	3.5 [2.4]
Posterior globe/optic nerve area	1.6 [1.2]	3.3 [2.1]
Total Intranasal Volume (cm³):	3.8 [2.4]	8.0 [4.5]

SD, standard deviation; cm², square centimeters; cm³, cubic centimeters

Mean differences in septal metrics were also compared between patients with and without septoplasty using independent samples t-testing. Comparisons in patient demographics and comorbidity, between patients with and without septoplasty, were completed using either independent samples t-testing or Pearson's chi-square tests. Type-I error probabilities (p-values) were reported for each comparison using a conventional alpha-level of 0.050 to identify significant differences. Because this study has a small sample size and was designed as an exploratory analysis, we elected to forgo correction for multiple comparisons which would reduce the false positive rate, but at the same time increase the false negative rate.

Results

Study population characteristics

A total of 74 study participants were included. Preoperative characteristics, PROMs, and measures of disease severity are further described in Table 1. The patient population was representative of tertiary care referral patterns, with 39% of patients carrying a diagnosis of CRSwNP, 50% of patients having previously undergone ESS, and patients presenting with a wide range of disease severity on both radiologic and endoscopic scoring systems (Table 1). A summary of mean septal deviation measurements for each described attribute are provided for the final cohort in Table 2, including deviation angles, areas, and volumes.

Association of radiologic measurements with PROMs and CRS severity measures

When examining the single Likert scale item query of the SNOT-

22 instrument which evaluates "Blockage / congestion of nose" there was weak correlation between the worst side septal deviation measures of the inferior turbinate area (R= -0.267; p=0.022), the crista galli area (R= -0.298; p=0.010), the posterior globe/optic nerve area (R= -0.370; p=0.001), and total intranasal volume (R= -0.352; p=0.002), whereas negative effect estimates reflect a worsening of nasal obstruction severity with decreasing areas and volumes (Table 3). Moreover, there was a weak correlation between SNOT-22 rhinologic domain scores and total worst side intranasal volume (R= -0.251; p=0.031; data not shown). Beyond these findings, no significant bivariate associations were found between any measurement of septal deviation and preoperative total SNOT-22 or total RSDI scores. Similarly, when examining non-rhinologic PROMs, no significant bivariate associations were found between any measurement of septal deviation and PHQ-2, SF-6D, or PSQI (R<0.200; p>0.050).

Additional correlation coefficients between septal deviation measurements for worst side and combined bilateral deviation with preoperative clinical measures of CRS disease severity are described in Table 4. The only statistically significant bivariate association was found between measure of combined bilateral deviation of the posterior globe/optic nerve area with Lund-Kennedy endoscopy scores (p=0.021) and BSIT total scores (p=0.017), however the magnitude of correlation was relatively weak (R<0.300).

Radiologic measurements and decision to perform septoplasty

Twenty five of the 74 total patients (34%) underwent concurrent septoplasty during ESS. No significant differences were found in any septal deviation measurement between study participants undergoing ESS with septoplasty compared to ESS without septoplasty for either worst side measurements or combined bilateral measurements (Table 5) on average. Patient characteristics and decision to perform septoplasty Demographics between patients with and without concurrent septoplasty during ESS were statistically similar (Table 6). Patients not undergoing a septoplasty were more likely to have revision sinus surgery (p<0.001), nasal polyposis (p=0.016) and oral corticosteroid dependence (p=0.024). There were no differences in endoscopic or radiologic disease severity measures, or olfaction scores in patients undergoing concurrent septoplasty compared to those that did not. A separate analysis examining potential differences in the study population based on nasal polyp status was performed without change in the presented results.

Discussion

Prior studies have demonstrated improvements in postoperative outcomes when a concurrent septoplasty is performed during endoscopic sinus surgery (ESS), however indications for Table 3. Correlations between measurements of preoperative septal deviation and patient-reported outcome measures (n=74).

Worst Side Measurements:	SNOT-22 "Blockage / congestion of nose" Item	SNOT-22 total score	RSDI total score	SF-6D Health utility score	PHQ-2 total score	PSQI total score
Angle (°):	R	R	R	R	R	R
Nasal bone angle	0.177	0.120	0.021	-0.039	-0.070	-0.003
Inferior turbinate angle	0.060	0.053	-0.130	0.045	-0.157	0.021
Crista galli angle	0.070	0.073	-0.046	0.045	-0.135	0.009
Posterior globe/optic nerve angle	0.111	0.153	0.103	-0.192	0.064	0.089
Intranasal Areas (cm²):						
Nasal bone area	-0.144	-0.100	-0.093	0.084	-0.100	-0.126
Inferior turbinate area	-0.267*	-0.097	-0.010	0.084	0.014	-0.164
Crista galli area	-0.298*	0.017	0.075	-0.057	0.158	-0.016
Posterior globe/optic nerve area	-0.370*	-0.085	0.028	-0.024	0.123	-0.086
Total Intranasal Volume (cm ³):	-0.352*	-0.157	-0.018	0.060	0.059	-0.124
Combined Bilateral Measurements	:					
Angle (°):						
Nasal bone angle	0.121	0.099	-0.053	-0.087	-0.036	0.002
Inferior turbinate angle	0.016	-0.002	-0.170	0.034	-0.156	-0.024
Crista galli angle	0.018	0.049	-0.141	0.113	-0.182	-0.029
Posterior globe/optic nerve angle	0.163	0.149	0.061	-0.191	0.116	0.024
Intranasal Areas (cm²):						
Nasal bone area	0.012	-0.108	-0.133	0.140	-0.185	-0.113
Inferior turbinate area	-0.161	-0.046	-0.022	0.082	-0.019	-0.153
Crista galli area	-0.287*	0.013	0.094	-0.070	0.158	-0.042
Posterior globe/optic nerve area	-0.355*	-0.072	0.043	-0.072	0.126	-0.134
Total Intranasal Volume (cm ³):	-0.265*	-0.104	0.009	0.031	0.073	-0.138

cm², square centimeters; cm³, cubic centimeters; R, either Pearson's correlation coefficient or Spearman's rank correlation coefficient for parametric or nonparametric distributions, respectively; SNOT-22, 22-item SinoNasal Outcome Test; RSDI, Rhinosinusitis Disability Index; PHQ-2, 2-item Patient Health Questionnaire; PSQI, Pittsburgh Sleep Quality Index. *Correlation is significant at the 0.050 level (two-tailed). **Correlation is significant below the 0.001 level (two-tailed).

performing septoplasty during ESS are not well defined ^(4, 5). This study sought to identify factors associated with concurrent septoplasty during ESS, and to help guide surgical decision making. Despite rigorous objective characterization of a wide spectrum of septal angles, nasal areas and volumes, we could not identify a convincing correlation between radiologic measurements with a battery of validated patient-reported and objective measures of disease, or surgeon decision to perform septoplasty. Using objective metrics to characterize nasal obstruction is not a novel concept. Many prior reports have attempted to correlate objective nasal measures with patient symptoms, but have had mixed success and generally fail to fully capture patient symptomatology. The most widely reported tools include acoustic rhinometry, rhinomanometry, and peak nasal inspiratory flow (PNIF) rates (22-25). Meanwhile, imaging studies have been shown to correlate strongly with acoustic rhinometry, however, patient

reports of nasal obstruction generally correlate poorly with CT findings and the use of imaging for the diagnosis of nasal obstruction is not recommended ⁽²⁶⁾.

Nonetheless, to our knowledge, objective nasal-related measures have not been used to account for differences in preoperative patient symptomatology with CRS-related metrics, or describe the indications for performing a concurrent septoplasty during ESS in a CRS patient population. While intranasal areas and volumes in this study did demonstrate a weak linear association with the SNOT-22 item that evaluates "blockage / congestion of nose," angles of septal deviation alone did not correlate with nasal blockage. This suggests that broader metrics may be more useful or representative of patient symptoms than simple deviations from midline, which likely fail to account for dynamic changes in lateral nasal wall structures, such as the inferior turbinates. It is also possible that feelings of congestion Table 4. Bivariate correlations between septal measurements for both "worst side" and "combined bilateral" deviation and preoperative clinical measures of disease severity (n=74).

Angle (°):RNasal bone angle0.017-0.070Inferior turbinate angle-0.112-0.048Crista galli angle0.058-0.115Posterior globe/optic nerve angle0.174-0.146	R -0.187 -0.107 -0.107 0.019 0.135
Inferior turbinate angle-0.112-0.048Crista galli angle0.058-0.115	-0.107 -0.107 0.019 0.135
Crista galli angle 0.058 -0.115	-0.107 0.019 0.135
	0.019 0.135
Posterior globe/optic nerve angle 0.174 -0.146	0.135
· · · · · · · · · · · · · · · · · · ·	0.135
Intranasal Areas (cm ²):	
Nasal bone area -0.051 0.004	
Inferior turbinate area -0.103 0.107	0.004
Crista galli area 0.007 0.111	0.047
Posterior globe/optic nerve area -0.003 0.128	-0.020
Total Intranasal Volume (cm3): -0.053 0.147	-0.091
Combined Bilateral Measurements:	
Angle (°):	
Nasal bone angle 0.060 -0.096	-0.105
Inferior turbinate angle -0.064 -0.014	-0.095
Crista galli angle 0.103 -0.089	0.030
Posterior globe/optic nerve angle 0.269* -0.280*	0.106
Intranasal Areas (cm ²):	
Nasal bone area -0.048 0.024	0.109
Inferior turbinate area -0.131 0.060	-0.005
Crista galli area -0.043 0.074	0.037
Posterior globe/optic nerve area -0.036 0.111	-0.060
Total Intranasal Volume (cm ³): -0.092 0.083	-0.083

cm², square centimeters; cm³, cubic centimeters; R, either Pearson's correlation coefficient or Spearman's rank correlation coefficient for parametric or nonparametric distributions, respectively; *Correlation is significant at the 0.050 level (two-tailed). **Correlation is significant below the 0.001 level (two-tailed).

could be secondary to sinonasal inflammation. As such, we are cautious to not overinterpret our findings as the overwhelming majority of preoperative nasal measurements in this study, both unilateral and combined, failed to demonstrate a correlation with the robust battery of CRS-related measures of disease. Beyond the association between the defined nasal-related measures and preoperative measures of disease, we attempted to identify characteristics that might influence surgeon decision to perform a concurrent septoplasty. There were however, no differences in septal metrics and the performance of septoplasty. Though demographics and medical comorbidities were similar between patients who underwent a concurrent septoplasty and those that did not, patients undergoing revision sinus surgery, patients with nasal polyposis, and patients with oral corticosteroid dependence were less likely to undergo a concurrent septoplasty. We suspect that concurrent septoplasty was less common in revision cases, because, if indicated, it likely would have been completed at the time of primary surgery. With the

same reasoning in mind, along with the increased incidence of revision ESS in patients with nasal polyposis, it is not surprising that nasal polyposis and oral corticosteroid dependence were less likely with a concurrent septoplasty.

Unfortunately, this study fails to capture the surgeons' reasoning for performing a septoplasty, and this cannot be captured retrospectively. The data presented here suggests that objective nasal measurements fail to fully represent a surgeon's decision to perform a concurrent septoplasty during ESS. Future studies should aim to capture a more detailed preoperative nasal and endoscopic analysis, as well as, ask surgeons to describe their rationale to perform a septoplasty at the time of surgery to minimize the risk of bias.

Though septal metrics in this study did not correlate with patient-reported QOL, the investigation by Smith et al. suggests that concurrent septoplasty improves postoperative symptomatology, specifically the ear/facial and psychological domains of the SNOT-22⁽⁵⁾. It is possible that nasal obstruction plays a

Table 5. Comparisons between septal measurements during ESS with or without septoplasty (n=74).

	ESS with septoplasty	ESS without septoplasty	
Angle (°):	(n=25)	(n=49)	p-value
	Mean [SD]	Mean [SD]	
Nasal bone angle	7.9 [3.2]	7.9 [2.5]	0.984
Inferior turbinate angle	11.1 [2.6]	10.7 [2.8]	0.531
Crista galli angle	8.2 [2.7]	8.2 [3.9]	0.952
Posterior globe/optic nerve angle	7.8 [4.0]	6.8 [3.7]	0.292
Intranasal Areas (cm²):			
Nasal bone area	1.8 [1.7]	1.6 [1.2]	0.548
Inferior turbinate area	1.5 [1.2]	1.4 [1.1]	0.614
Crista galli area	1.9 [1.7]	1.7 [1.3]	0.609
Posterior globe/optic nerve area	1.7 [1.2]	1.6 [1.2]	0.829
Total Intranasal Volume (cm3):	3.5 [2.0]	4.0 [2.6]	0.443
Total Intranasal Volume (cm3):	-0.053	0.147	-0.091
Combined Bilateral Measurements:			
Angle (°):	12.7 [3.7]	13.4 [3.9]	0.434
Inferior turbinate angle	18.0 [3.5]	18.6 [4.8]	0.592
Crista galli angle	12.8 [3.1]	13.8 [5.4]	0.374
Posterior globe/optic nerve angle	11.5 [3.9]	11.6 [4.9]	0.919
Intranasal Areas (cm²):			
Nasal bone area	3.5 [2.0]	3.1 [2.1]	0.485
Inferior turbinate area	3.4 [2.4]	2.7 [1.5]	0.123
Crista galli area	4.4 [3.0]	3.1 [1.8]	0.067
Posterior globe/optic nerve area	3.8 [2.5]	3.0 [1.8]	0.158
Total Intranasal Volume (cm ³):	8.1 [3.7]	8.0 [4.9]	0.933

ESS, endoscopic sinus surgery;°, degrees; cm², square centimeters; cm³, cubic centimeters.

role in sleep quality and subsequently in mood, cognition and psychological aspects of QOL. Because of this, we investigated additional, non-CRS PROMs, but failed to identify additional associations. Further characterization of patient-reported nasal airway obstruction is possible with additional metrics, such as the Nasal Obstruction and Septoplasty Effectiveness (NOSE) Scale, however this instrument is not routinely captured in the CRS population.

This study highlights the difficulty in identifying correlations between patient symptomology and objective measures as they relate to concurrent septoplasty during ESS. Two recent reports highlight the controversy between objective and subjective measures of nasal obstruction outcomes^(26, 27). Nonetheless, beyond patient symptoms, it is intuitive that there is an underlying structural change in anatomy that accounts for postoperative symptom improvement. Alternative strategies of assessing nasal airflow, may have been be more useful in this current analysis, and we suspect that a portion of this answer might be better explained by computational fluid dynamics (CFD) technology, which is able to identify specific drivers of reduced airflow⁽²⁸⁾. Overall, though this is a "negative" study, there are many strengths. The overarching scientific inquiry and study design is based in an important clinical question that attempts to identify metrics that could improve patient outcomes for a common condition. The prospective and multi-institutional nature of this study, along with a robust battery of validated subjective and objective CRS-related measures adds to its strengths. However, the relatively small sample size of this exploratory study limits statistical power. Furthermore, given the conceivable likelihood of a Type I statistical error, statistically significant results should be cautiously interpreted. Future studies should specifically examine other nasal characteristics, not assessed in this analysis, such as concomitant inferior turbinate hypertrophy, the presence of anatomical variants such as a concha bullosa, the extent of surgical access required, as well as alternative methods of intranasal evaluation, such as CFD. Additionally, forthcoming investigations should query surgeons at the time of surgery to delineate the reasoning for performing, or not performing, a

Table 6. Comparisons of preoperative demographics, patient characteristics, and comorbidity between study participants with and without concurrent septoplasty during endoscopic sinus surgery (n=74).

Mean [SD] N(%) Mean [SD] N(%) p-value Age at enrollment (years) 53.6 [16.0] 58.5 [12.4] 0.149 Female* 12 (48%) 28 (57%) Male* 13 (52%) 21 (43%) 0.455 Race: White/Caucasian 25 (100%) 44 (90%) African American 0(0%) 48 (98%) Non-Hispanic/Latino 0(0%) 12(2%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) Nasal polyposis 11 (44%) 18 (37%) 0.561 Allergy (positive mAST/skin prick) 11 (44%) 18 (37%) 0.541 Dipperssion*		Septoplasty (n=25)		No Septoplasty (n=49)		
Female* 12 (48%) 28 (57%) Male* 13 (52%) 21 (43%) 0.455 Race: White/Caucasian 25 (100%) 44 (90%) African American 0 (0%) 5 (10%) 0.098 Ethnicity: Non-Hispanic/Latino 25 (100%) 48 (98%) Revision sinus surgery 0 (0%) 12%) 0.472 Madical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <-0-01 Nasal polyposis Relical history / comorbid diagnoses: 14 (4%) 14 (49%) 0.0016 Asthma </th <th></th> <th>Mean [SD]</th> <th>N (%)</th> <th>Mean [SD]</th> <th>N (%)</th> <th>p-value</th>		Mean [SD]	N (%)	Mean [SD]	N (%)	p-value
Male* 13 (52%) 21 (43%) 0.455 Race: White/Caucasian 0(0%) 44 (90%) African American 0(0%) 5 (10%) 0.098 Ethnicity: Non-Hispanic/Latino 25 (100%) 48 (98%) Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <-0.011 Nasal polyposis Asthma	Age at enrollment (years)	53.6 [16.0]		58.5 [12.4]		0.149
Race: 44 (90%) Mhite/Caucasian 25 (100%) 44 (90%) African American 0 (0%) 5 (10%) 0.098 Ethnicity: Non-Hispanic/Latino 0 (0%) 48 (98%) Hispanic/Latino 0 (0%) 12%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <-0.01	Female*		12 (48%)		28 (57%)	
White/Caucasian 25 (100%) 44 (90%) African American 0 (0%) 5 (10%) 0.098 Ethnicity: Non-Hispanic/Latino 0 (0%) 48 (98%) Hispanic/Latino 0 (0%) 1 (2%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <-0.01	Male*		13 (52%)		21 (43%)	0.455
African American 0 (0%) 5 (10%) 0.098 Ethnicity: Non-Hispanic/Latino 0 (0%) 48 (98%) Hispanic/Latino 0 (0%) 1 (2%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <0.001	Race:					
Ethnicity: 48 (98%) Non-Hispanic/Latino 0 (0%) 1 (2%) 0.472 Medical history / comorbid diagnoses: 0 (0%) 1 (2%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <0.011	White/Caucasian		25 (100%)		44 (90%)	
Non-Hispanic/Latino 25 (100%) 48 (98%) Hispanic/Latino 0 (0%) 1 (2%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <0.016	African American		0 (0%)		5 (10%)	0.098
Hispanic/Latino 0 (0%) 1 (2%) 0.472 Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <-0.01 Nasal polyposis 5 (20%) 24 (49%) 0.016 Asthma 7 (28%) 6 (12%) 0.561 ASA sensitivity 11 (4%) 6 (12%) 0.411 Allergy (positive mRAST/skin prick) 11 (4%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 12 (2%) 0.244 Oral corticosteroid dependency 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 9 (18%) 0.024 Measures of Disease Severity: 7 (2 [3.8] 0.301 BSIT total score 9 (2 [2.8] <	Ethnicity:					
Medical history / comorbid diagnoses: Revision sinus surgery 5 (20%) 32 (65%) <0.001	Non-Hispanic/Latino		25 (100%)		48 (98%)	
Revision sinus surgery 5 (20%) 32 (65%) <0.001 Nasal polyposis 5 (20%) 24 (49%) 0.016 Asthma 7 (28%) 17 (35%) 0.561 ASA sensitivity 1 (4%) 6 (12%) 0.411 Allergy (positive mRAST/skin prick) 11 (44%) 18 (37%) 0.545 Depression* 5 (20%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 1 (2%) >0.999 Alcohol use 0 (0%) 9 (18%) 0.024 Oral corticosteroid dependency 0 (0%) 9 (18%) >0.999 Measures of Disease Severity: 1 >0.999 >0.999 Iund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 8 (32%)	Hispanic/Latino		0 (0%)		1 (2%)	0.472
Nasal polyposis 5 (20%) 24 (49%) 0.016 Asthma 7 (28%) 17 (35%) 0.561 ASA sensitivity 1 (4%) 6 (12%) 0.411 Allergy (positive mRAST/skin prick) 11 (44%) 18 (37%) 0.545 Depression* 5 (20%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 1 (2%) >0.999 Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Medical history / comorbid diagnoses:					
Asthma 7 (28%) 17 (35%) 0.561 ASA sensitivity 1 (4%) 6 (12%) 0.411 Allergy (positive mRAST/skin prick) 11 (4%) 18 (37%) 0.545 Depression* 5 (20%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 1 (2%) >0.999 Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Masures of Disease Severity: 0.001 >0.0108 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Revision sinus surgery		5 (20%)		32 (65%)	<0.001
ASA sensitivity 1 (4%) 6 (12%) 0.411 Allergy (positive mRAST/skin prick) 11 (4%) 18 (37%) 0.545 Depression* 5 (20%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 4 (8%) >0.999 Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 5 (10%) >0.999 Lund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Nasal polyposis		5 (20%)		24 (49%)	0.016
Allergy (positive mRAST/skin prick) 11 (44%) 18 (37%) 0.545 Depression* 5 (20%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 1 (2%) >0.999 Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 5 (10%) >0.099 BIT total score 9.2 [2.8] 7.2 [3.8] 0.108 Abnormal olfaction (score < 8)	Asthma		7 (28%)		17 (35%)	0.561
Depression* 5 (20%) 4 (8%) 0.141 Tobacco use/smoking 0 (0%) 1 (2%) >0.999 Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 5 (10%) >0.999 ILund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	ASA sensitivity		1 (4%)		6 (12%)	0.411
Tobacco use/smoking 0 (0%) 1 (2%) >0.999 Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 5 (10%) >0.999 ILund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Allergy (positive mRAST/skin prick)		11 (44%)		18 (37%)	0.545
Alcohol use 14 (56%) 20 (42%) 0.244 Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 5 (10%) >0.301 Lund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8) 8 (32%) 22 (47%) 0.225	Depression*		5 (20%)		4 (8%)	0.141
Oral corticosteroid dependency 0 (0%) 9 (18%) 0.024 Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: 5 (10%) >0.099 Lund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Tobacco use/smoking		0 (0%)		1 (2%)	>0.999
Diabetes mellitus (Type I / II) 2 (8%) 5 (10%) >0.999 Measures of Disease Severity: Lund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8) 8 (32%) 22 (47%) 0.225	Alcohol use		14 (56%)		20 (42%)	0.244
Measures of Disease Severity: Lund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Oral corticosteroid dependency		0 (0%)		9 (18%)	0.024
Lund-Kennedy endoscopy score 6.2 [3.2] 7.2 [3.8] 0.301 BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Diabetes mellitus (Type I / II)		2 (8%)		5 (10%)	>0.999
BSIT total score 9.2 [2.8] 7.7 [3.6] 0.108 Abnormal olfaction (score < 8)	Measures of Disease Severity:					
Abnormal olfaction (score < 8) 8 (32%) 22 (47%) 0.225	Lund-Kennedy endoscopy score	6.2 [3.2]		7.2 [3.8]		0.301
	BSIT total score	9.2 [2.8]		7.7 [3.6]		0.108
Lund-Mackay CT score 13.3 [6.8] 13.6 [6.1] 0.841	Abnormal olfaction (score < 8)		8 (32%)		22 (47%)	0.225
	Lund-Mackay CT score	13.3 [6.8]		13.6 [6.1]		0.841

*self-reported; SD, standard deviation; ESS, endoscopic sinus surgery; ASA, acetylsalicylic acid; BSIT, Brief Smell Identification Test; mRAST, modified radioallergosorbent testing, CT, computed tomography.

concurrent septoplasty during ESS. An alternative consideration would be to perform a randomised trial of the performance of a concurrent septoplasty.

Conclusion

Though prior studies have suggested improved patient outcomes in the setting of a concurrent septoplasty during ESS, this study failed to demonstrate an association between radiologic septal-related measurements with preoperative patient characteristics or symptomatology when patients undergo ESS with or without a concurrent septoplasty. Based on these results, static radiologic measures should not be used alone in a surgeon's decision-making algorithm to perform a concurrent septoplasty. Nonetheless, prior literature is compelling that septoplasty improves ESS-related outcomes and future studies should attempt to elucidate the underlying mechanism of improved outcomes.

Acknowledgements

This work was supported by a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, Bethesda, MD (3R01 DC005805). Public clinical trial registration (www.clinicaltrials. gov) ID# NCT02720653.

Authorship contribution

NRR: data collection, data analysis, interpretation of results, and preparation of manuscript. ZMS: study design, patient enrollment, data analysis, interpretation of results, and revision of manuscript. JCM: data analysis, interpretation of results, and preparation of manuscript. MPC: data collection and analysis CP: data collection and analysis. RHJ: data collection and analysis. TLS: study design, patient enrollment, interpretation of results, and revision of manuscript. RJS: study design, patient enrollment, data analysis, interpretation of results, and revision of manuscript.

Conflict of interest

No financial disclosures of conflicts of interest exist for NRR, JCM,

References

- Rhee JS, Sullivan CD, Frank DO, Kimbell JS, Garcia GJ. A systematic review of patientreported nasal obstruction scores: defining normative and symptomatic ranges in surgical patients. JAMA Facial Plast Surg.. 2014; 16: 219-25; quiz 32.
- Soler ZM, Jones R, Le P, et al. Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis. Laryngoscope. 2018; 128: 581-92.
- Rudmik L, Mace J, Ferguson BJ, Smith TL. Concurrent septoplasty during endoscopic sinus surgery for chronic rhinosinusitis: does it confound outcomes assessment? Laryngoscope. 2011; 121: 2679-83.
- Rudmik L, Xu Y, Alt JA, et al. Evaluating Surgeon-Specific Performance for Endoscopic Sinus Surgery. JAMA Otolaryngol Head Neck Surg. 2017; 143: 891-8.
- Smith TL, Mace JC, Rudmik L, et al. Comparing surgeon outcomes in endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope. 2017; 127: 14-21.
- Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. 2007; 137: S1-31.
- DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017; 127: 550-5.
- Levy JM, Mace JC, Sansoni ER, Soler ZM, Smith TL. Longitudinal improvement and stability of olfactory function in the evaluation of surgical management for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016; 6: 1188-95.
- Levy JM, Mace JC, DeConde AS, Steele TO, Smith TL. Improvements in psychological dysfunction after endoscopic sinus surgery for patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016; 6: 906-13.
- El Rassi E, Mace JC, Steele TO, Alt JA and Smith TL. Improvements in sleep-related symptoms after endoscopic sinus surgery in patients with chronic rhinosinusitis. Int

MPC, CP, RHJ or TLS. ZMS is a consultant for Olympus and 480 Biomedical as well as on the advisory board for Regeneron. RJS is consultant for Olympus and Stryker and has received grant support from Entellus and Intersect. There are no other financial disclosures or conflicts of interest for any other author.

Forum Allergy Rhinol. 2016; 6: 414-22.

- 11. El Rassi E, Mace JC, Steele TO, et al. Sensitivity analysis and diagnostic accuracy of the Brief Smell Identification Test in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016; 6: 287-92.
- Alt JA, DeConde AS, Mace JC, Steele TO, Orlandi RR, Smith TL. Quality of Life in Patients With Chronic Rhinosinusitis and Sleep Dysfunction Undergoing Endoscopic Sinus Surgery: A Pilot Investigation of Comorbid Obstructive Sleep Apnea. JAMA Otolaryngol Head Neck Surg. 2015; 141: 873-81.
- Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997; 117: S35-40.
- Doty RL, Marcus A, Lee WW. Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT). Laryngoscope. 1996; 106: 353-6.
- 15. Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993; 31: 183-4.
- Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009; 34: 447-54.
- Piccirillo JF, Merritt MG, Jr., Richards ML. Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol Head Neck Surg. 2002; 126: 41-7.
- Benninger MS, Senior BA. The development of the Rhinosinusitis Disability Index. Arch Otolaryngol Head Neck Surg. 1997; 123: 1175-9.
- 19. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004; 42: 851-9.
- Arroll B, Goodyear-Smith F, Crengle S, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010; 8: 348-53.
- Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28: 193-213.
- 22. Bermuller C, Kirsche H, Rettinger G,

Riechelmann H. Diagnostic accuracy of peak nasal inspiratory flow and rhinomanometry in functional rhinosurgery. Laryngoscope. 2008; 118: 605-10.

- Chin D, Marcells G, Malek J, et al. Nasal peak inspiratory flow (NPIF) as a diagnostic tool for differentiating decongestable from structural nasal obstruction. Rhinology. 2014; 52: 116-21.
- Chaves C, de Andrade CR, Ibiapina C. Objective measures for functional diagnostic of the upper airways: practical aspects. Rhinology. 2014; 52: 99-103.
- 25. Ottaviano G, Fokkens WJ. Measurements of nasal airflow and patency: a critical review with emphasis on the use of peak nasal inspiratory flow in daily practice. Allergy. 2016; 71: 162-74.
- 26. Spataro E, Most SP. Measuring Nasal Obstruction Outcomes. Otolaryngol Clin North Am. 2018; 51: 883-95.
- 27. Hong SD, Lee NJ, Cho HJ, et al. Predictive factors of subjective outcomes after septoplasty with and without turbinoplasty: can individual perceptual differences of the air passage be a main factor? Int Forum Allergy Rhinol. 2015; 5: 616-21.
- Gamerra M, Cantone E, Sorrentino G, et al. Mathematical model for preoperative identification of obstructed nasal subsites. Acta Otorhinolaryngol Ital. 2017; 37: 410-5.

Nicholas R. Rowan, MD 601 N. Caroline St, 6th Floor, Ste 6164 Baltimore MD 21287 USA

Tel: 410-955-2307 E-mail: nrowan1@jhmi.edu